摘要
目的探讨^(125)I粒子植入联合化疗在中晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中的疗效。方法选取2019年2月至2022年4月枣庄市胸科医院收治的105例中晚期NSCLC患者作为研究对象,按照随机数字表法分为对照组(n=52)与观察组(n=53)。对照组采用常规化疗,观察组在对照组基础上加用^(125)I粒子植入治疗。比较两组血清肿瘤标志物[癌胚抗原(carcinoembryonic antigen,CEA)、鳞状细胞癌相关抗原(squamous cell carcinoma antigen,SCC-Ag)及细胞角质蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,CYFRA21-1)]水平、疾病控制效果、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+))、不良反应发生率及生命质量[Karnofsky功能状态评分(Karnofsky performance status score,KPS)]。结果治疗后,观察组血清CEA、SCC-Ag、CYFRA21-1水平均低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义;治疗后,观察组KPS评分高于对照组,差异有统计学意义(P<0.05)。结论^(125)I粒子植入联合化疗应用于中晚期NSCLC患者中,可增强疾病控制效果,降低血清肿瘤标志物水平,提升机体免疫功能,且不会增加不良反应的发生,利于提升患者生命质量。
Objective To explore the efficacy of ^(125)I seed implantation combined with chemotherapy in patients with advanced-stage non-small cell lung cancer(NSCLC).Methods 105 patients with advanced-stage NSCLC in Zaozhuang Chest Hospital from February 2019 to April 2022 were selected as the research subjects,and they were divided into the control group(n=52)and the observation group(n=53)according to the random number table method.The control group was treated with conventional chemotherapy,and the observation group was treated with ^(125)I seed implantation on the basis of the control group.The levels of serum tumor markers(carcinoembryonic antigen[CEA],squamous cell carcinoma antigen[SCC-Ag]and cytokeratin 19 fragment antigen 21-1[CYFRA21-1]),disease control effect,immune function indexes(CD3^(+),CD4^(+),CD8^(+)levels and CD4^(+)/CD8^(+)),adverse reactions and quality of life(Karnofsky performance status score[KPS])were compared between the two groups.Results After treatment,the levels of serum CEA,SCC Ag and CYFRA21-1 in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.After treatment,the KPS score in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion ^(125)I seed implantation combined with chemotherapy in patients with advanced-stage NSCLC can enhance the disease control effect,reduce the levels of serum tumor markers,improve the immune function of the body,and will not increase the occurrence of adverse reactions,which is conducive to improving the quality of life of patients.
作者
王晓明
赵亮
鲍丰瑜
WANG Xiaoming;ZHAO Liang;BAO Fengyu(Minimally Invasive Comprehensive Treatment Center for Tumors,Zaozhuang Chest Hospital/Zaozhuang Cancer Hospital,Zaozhuang,Shandong,277599,China;Department of Tumor,Tengzhou Workers'Hospital,Zaozhuang,Shandong,277599,China;Department of Infection Management,Zaozhuang Chest Hospital/Zaozhuang Tumor Hospital,Zaozhuang,Shandong,277599,China)
出处
《当代医学》
2025年第9期37-41,共5页
Contemporary Medicine
